Quarterly Earnings

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

With a major strategic pivot complete, Gibraltar Industries' leadership will outline its 2026 playbook to investors at a key 'New Ideas' conference.

Adaptive posted a 55% revenue surge in 2025, fueled by its clonoSEQ cancer test. Now, the firm is charting a clear course to company-wide profitability.

BioXcel Therapeutics is pushing its drug IGALMI® for home use, a move that could transform mental healthcare but carries significant financial and safety risks.

As subsea tech leader Kraken Robotics sees explosive growth, it brings on veteran Terra Penrose as Chief People Officer to scale its global workforce.

As WD-40 leaders prepare for the ICR Conference, investors weigh strong growth plans against a recent earnings miss and a major brand overhaul.

As Triumph Financial preps its Q4 2025 results, investors watch to see if its tech investments can deliver on high growth expectations amid a complex freight market.

IDEXX prepares to release its 2025 results, with all eyes on whether its high-tech product launches can sustain momentum in a complex pet care market.

Beyond a simple time change, Fortrea's upcoming JPM presentation is a critical test for its new CEO and a key moment to define its future in the CRO market.

As Encompass Health sets its Q4 earnings date, investors watch to see if the rehab giant can sustain its impressive 2025 growth amid industry pressures.

With record revenue and a bold AI strategy, Opera heads to a key investor conference. Can its 'agentic' browsers redefine the web and win market share?

Upbound Group's new CEO and CFO head to the prestigious ICR Conference. Investors await insights on growth, credit trends, and financial inclusion strategy.

Ocugen heads to a top investor conference with a bold plan for its gene-agnostic therapy, aiming to treat blindness and secure its future in a crowded market.

With blockbuster preliminary sales and rapid patient adoption, Liquidia's new inhaled therapy is challenging established players in the lung disease space.

Pandora's 2025 growth slows amid weak consumer sentiment, but a new CEO plans a strategic reset to combat rising costs and boost brand desirability.

Sanuwave Health posts record revenue, defying industry-wide turmoil as reimbursement cuts reshape the advanced wound care market. How did they do it?

With a 12% increase in gold reserves, Aris Mining's Segovia mine proves its mettle as a world-class asset, fueling an aggressive expansion in South America.

Operational failures at a key Texas plant and a sudden drop in chlorine demand force chemical giant Olin Corp. to drastically cut its Q4 earnings forecast.

Collegium Pharmaceutical projects robust 2026 revenue fueled by its ADHD drug Jornay PM, savvy debt refinancing, and a proactive generic strategy.

The opioid treatment specialist projects over $1.1B in revenue, driven by its flagship drug SUBLOCADE and a major strategic overhaul in the U.S.